Aleix Prat: Patient-Level Meta-Analysis of HER2DX in Early-Stage HER2-Positive Breast Cancer
Aleix Prat, Director of Cancer Institute and Blood Disorders at the Hospital Clinic of Barcelona, shared a post on LinkedIn:
“Our new article published in The Lancet Oncology
Very proud to share our latest work on the HER2DX genomic test in early-stage HER2-positive breast cancer.
In this individual patient-level meta-analysis (n = 2,518 patients across 11 studies), HER2DX provides clinically meaningful prognostic stratification, beyond standard clinical–pathological variables and pCR. These results reinforce its value as a clinical tool in precision oncology.
Huge thanks to Dr. Guillermo Villacampa, first author, for his outstanding work, dedication, and leadership throughout this project. And to Dr. Sara Tolaney, senior author, for her continuous support and brilliant scientific guidance.
Thanks also to all co-authors and research teams involved in this collaborative effort. And to REVEAL GENOMICS for supporting this project.
Title: HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
Authors: Guillermo Villacampa, Tomás Pascual, Paolo Tarantino, Javier Cortés, José Perez-García, Antonio Llombart-Cussac, Prof Pierfranco Conte, Mario Mancino, Valentina Guarneri, Maria Vittoria Dieci, Adrienne G Waks, Francesco Schettini, Fara Brasó-Maristany, Gaia Griguolo, Beatriz Alonso de Castro, Cristina Reboredo, Silvia Antolín, Coralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, Sara M Tolaney
Read the Full Article.
More posts featuring Aleix Prat.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023